Ongoing clinical trials in molecular imaging and radiotheranostics. Sorted by date of last update.
Lu-177-DOTA-EB-TATE in Adult Patients with Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Phase 1
Last update: June 12
Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies (PROSTEPIRM)
N/A
Radiation Medication (Radium-223 Dichloride) versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Last update: June 11
Phase I Study of Ac-225-J591 Plus Lu-177-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones
Phase 2
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men with Advanced Prostate Cancer with Bone Metastasis
Testing Lutetium Lu-177 Dotatate in Patients with Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Y-90 Treatment Response Using Transarterial Radioembolization (TARE)
Last update: June 10
A Phase I/II, Dose Finding and Optimization Study of [Lu-177]Lu-NeoB in Combination with Capecitabine in Patients with GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination with a CDK4/6 Inhibitor. (NeoB-Cap1)
Evaluation of [⁶⁸Ga/¹⁷⁷Lu]HT547: Safety, Biodistribution, and Dosimetry in Solid Tumors
Early Phase 1